1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

‘The US Is Catching Up’ – Accord’s Kokino On Biosimilar Market Dynamics

Firm’s US President Talks PBMs, The Inflation Reduction Act And Interchangeability

 
• By Dave Wallace

In the second part of his interview with Generics Bulletin, Chrys Kokino – president of Accord US – talks about how the US biosimilars market is catching up with Europe, as well as discussing aspects such as PBMs, the Inflation Reduction Act and biosimilar interchangeability.

Syringe in vial in front of US flag
The US biosimilars market is catching up with Europe, Kokino says • Source: Shutterstock

After discussing Accord BioPharma’s strategy for US biosimilars in the first part of his interview with Generics Bulletin (see sidebar), Chrys Kokino, president of Accord US, also discussed the country’s biosimilars market more broadly, including how quickly it was catching up with the market in Europe.

“A lot’s evolved,” he acknowledged. “But when I compare what’s happened in Europe versus what happened here in the US, clearly Europe is way ahead of us

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.